A
4.41
0.13 (3.04%)
| Penutupan Terdahulu | 4.28 |
| Buka | 4.45 |
| Jumlah Dagangan | 80,882 |
| Purata Dagangan (3B) | 788,574 |
| Modal Pasaran | 118,938,576 |
| Harga / Buku (P/B) | 0.590 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -2.38 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.95% |
| Nisbah Semasa (MRQ) | 13.10 |
| Aliran Tunai Operasi (OCF TTM) | -45.93 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -35.43 M |
| Pulangan Atas Aset (ROA TTM) | -32.36% |
| Pulangan Atas Ekuiti (ROE TTM) | -56.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Alto Neuroscience, Inc. | Menurun | - |
AISkor Stockmoo
-0.8
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.75 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 7.51% |
| % Dimiliki oleh Institusi | 91.30% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Alpha Wave Global, Lp | 30 Sep 2024 | 3,707,757 |
| Ra Capital Management, L.P. | 30 Sep 2024 | 2,075,154 |
| 72 Investment Holdings, Llc | 30 Sep 2024 | 667,778 |
| Vestal Point Capital, Lp | 30 Sep 2024 | 650,000 |
| Awm Investment Company, Inc. | 30 Sep 2024 | 559,731 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 18.00 (Jones Trading, 308.16%) | Beli |
| Median | 10.00 (126.76%) | |
| Rendah | 4.00 (Wedbush, -9.30%) | Pegang |
| Purata | 10.50 (138.10%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 4.25 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jones Trading | 16 Dec 2024 | 18.00 (308.16%) | Beli | 3.75 |
| Stifel | 13 Nov 2024 | 10.00 (126.76%) | Beli | 4.53 |
| Baird | 23 Oct 2024 | 10.00 (126.76%) | Beli | 4.36 |
| Wedbush | 23 Oct 2024 | 4.00 (-9.30%) | Pegang | 4.36 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Dec 2024 | Pengumuman | Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology |
| 12 Nov 2024 | Pengumuman | Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
| 04 Nov 2024 | Pengumuman | Alto Neuroscience to Participate in Upcoming Investor Conferences |
| 22 Oct 2024 | Pengumuman | Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |